by Barry101 | Sep 11, 2023 | Press Release
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in...
by Barry101 | Sep 5, 2023 | Press Release
OCALA, Fla., Sept. 05, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment...
by Barry101 | Aug 23, 2023 | Press Release
Group Seeking to Take Control of 75% of AIM Board Failed to Properly Disclose Myriad Interconnections, Understandings and Arrangements Among Its Members – Violating the Company’s Bylaws and Preventing Shareholders from Being Able to Make Fully Informed...
by Barry101 | Aug 15, 2023 | Press Release
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and webcast today at 8:30 AM ET OCALA, Fla., Aug. 15, 2023 — AIM...
by Barry101 | Aug 9, 2023 | Press Release
OCALA, Fla., Aug. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q2 2023 operational and financial...